A recent Pharmaceutical Business Review article discussed the US launch of GW Pharmaceuticals’ cannabis-derived medication. EPIDIOLEX is an oral solution used to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome. It received FDA approval back in June of 2018, but is just now available in America.
EPIDIOLEX offers hope for patients suffering from the rare forms of childhood-onset epilepsy who have not had success with other seizure medications. The clinical development program consisted of three randomized, controlled Phase 3 clinical trials and an open-label extension study. GW also launched a patient support program called EPIDIOLEX Engage, which helps patients who have been prescribed the drug gain access to the therapy.
.jpg?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=146&w=340)
